Overview

Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to determine the maximum tolerated dose (MTD) of Oratecan in combination with capecitabine
Phase:
Phase 1
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Treatments:
Camptothecin
Capecitabine
Irinotecan